Deletion of the P2X7 nucleotide receptor reveals its regulatory roles in bone formation and resorption

被引:227
作者
Ke, HZ
Qi, H
Weidema, AF
Zhang, Q
Panupinthu, N
Crawford, DT
Grasser, WA
Paralkar, VM
Li, M
Audoly, LP
Gabel, CA
Jee, WSS
Dixon, SJ
Sims, SM
Thompson, DD
机构
[1] Pfizer Global Res & Dev, Osteoporosis Res, Groton Labs, Groton, CT 06340 USA
[2] Univ Western Ontario, Canadian Inst Hlth, Res Grp Skeletal Dev & Remodeling, London, ON N6A 5C1, Canada
[3] Univ Western Ontario, Dept Physiol & Pharmacol, London, ON N6A 5C1, Canada
[4] Univ Utah, Sch Med, Div Radiobiol, Salt Lake City, UT 84108 USA
关键词
D O I
10.1210/me.2003-0021
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The P2X(7) nucleotide receptor is an ATP-gated ion channel expressed widely in cells of hematopoietic origin. Our purpose was to explore the involvement of the P2X(7) receptor in bone development and remodeling by characterizing the phenotype of mice genetically modified to disrupt the P2X(7) receptor [knockout (KO)]. Femoral length did not differ between KO and wild-type (WT) littermates at 2 or 9 months of age, indicating that the P2X(7) receptor does not regulate longitudinal bone growth. However, KO mice displayed significant reduction in total and cortical bone content and periosteal circumference in femurs, and reduced periosteal bone formation and increased trabecular bone resorption in tibias. Patch clamp recording confirmed expression of functional P2X(7) receptors in osteoclasts from WT but not KO mice. Osteoclasts were present in vivo and formed in cultures of bone marrow from KO mice, indicating that this receptor is not essential for fusion of osteoclast precursors. Functional P2X(7) receptors were also found in osteoblasts from WT but not KO mice, suggesting a direct role in bone formation. P2X(7) receptor KO mice demonstrate a unique skeletal phenotype that involves deficient periosteal bone formation together with excessive trabecular bone resorption. Thus, the P2X(7) receptor represents a novel therapeutic target for the management of skeletal disorders such as osteoporosis.
引用
收藏
页码:1356 / 1367
页数:12
相关论文
共 26 条
[1]   Cutting edge: A natural P451L mutation in the cytoplasmic domain impairs the function of the mouse P2X7 receptor [J].
Adriouch, S ;
Dox, C ;
Welge, V ;
Seman, M ;
Koch-Nolte, F ;
Haag, F .
JOURNAL OF IMMUNOLOGY, 2002, 169 (08) :4108-4112
[2]  
Armstrong JN, 2002, J NEUROSCI, V22, P5938
[3]   The frequency of common progenitors for adipocytes and osteoblasts and of committed and restricted adipocyte and osteoblast progenitors in fetal rat calvaria cell populations [J].
Bellows, CG ;
Heersche, JNM .
JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 (11) :1983-1993
[4]   The past, present and future of purine nucleotides as signalling molecules [J].
Burnstock, G .
NEUROPHARMACOLOGY, 1997, 36 (09) :1127-1139
[5]   Non-genomic inhibition of human P2X7 purinoceptor by 17β-oestradiol [J].
Cario-Toumaniantz, C ;
Loirand, G ;
Ferrier, L ;
Pacaud, P .
JOURNAL OF PHYSIOLOGY-LONDON, 1998, 508 (03) :659-666
[6]   Spontaneous cell fusion in macrophage cultures expressing high levels of the P2Z/P2X(7) receptor [J].
Chiozzi, P ;
Sanz, JM ;
Ferrari, D ;
Falzoni, S ;
Aleotti, A ;
Buell, GN ;
Collo, G ;
DiVirgilio, F .
JOURNAL OF CELL BIOLOGY, 1997, 138 (03) :697-706
[7]   Tissue distribution of the P2X(7) receptor [J].
Collo, G ;
Neidhart, S ;
Kawashima, E ;
KoscoVilbois, M ;
North, RA ;
Buell, G .
NEUROPHARMACOLOGY, 1997, 36 (09) :1277-1283
[8]  
Dixon SJ, 2000, DRUG DEVELOP RES, V49, P187, DOI 10.1002/(SICI)1098-2299(200003)49:3<187::AID-DDR9>3.0.CO
[9]  
2-F
[10]   Extracellular ATP activates transcription factor NF-κB through the P2Z purinoreceptor by selectively targeting NF-κB p65 (RelA) [J].
Ferrari, D ;
Wesselborg, S ;
Bauer, MKA ;
Schulze-Osthoff, K .
JOURNAL OF CELL BIOLOGY, 1997, 139 (07) :1635-1643